HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Office of Cosmetics & Colors transfer to CDER would not be cost effective for FDA.

This article was originally published in The Rose Sheet

Executive Summary

OFFICE OF COSMETICS & COLORS' TRANSFER TO CDER WOULD NOT BE COST EFFECTIVE for FDA, the Cosmetic, Toiletry and Fragrance Association maintains in a recent "white paper" responding to an agency suggestion that the cosmetics regulatory office move into the Center for Drug Research & Evaluation. "No FDA savings [would] result from transfer of the cosmetics regulatory program" from the Center for Food Safety & Applied Nutrition to CDER, the trade group asserts. "At least the same number of personnel and the same amount of funding will be necessary to establish and maintain an effective cosmetics regulation program at CDER as at CFSAN....Not a single person and not a single dollar will be saved by making a transfer to CDER," the trade association asserts.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS005206

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel